Evidence map›Paper›PMID 38547779›Full record

ArticleOral oncology2024

An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.

Vasiliki Xirou, Myrto Moutafi, Yalai Bai, Thazin Nwe Aung, Sneha Burela, Matthew Liu, Randall J Kimple, Fahad Shabbir Ahmed, Bryant Schultz, Douglas Flieder and 4 more

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Digital pathology in tau research: A comparison of QuPath and HALO.Journal of neuropathology and experimental neurology · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Vasiliki XirouDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Myrto MoutafiDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Yalai BaiDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Thazin Nwe AungDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Sneha BurelaDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Matthew LiuDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Randall J KimpleDepartment of Human Oncology and UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Fahad Shabbir AhmedDepartment of Pathology, Wayne State University School of Medicine, Detroit, MI, USA.
Bryant SchultzBiosample Repository Facility, Fox Chase Cancer Center, Philadelphia, PA, USA.
Douglas FliederDepartment of Pathology, Fox Chase Cance Center, Philadelphia, PA, USA.
Denise C ConnollyBiosample Repository Facility, Fox Chase Cancer Center, Philadelphia, PA, USA; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Amanda PsyrriDepartment of Internal Medicine (Medical Oncology), National and Kapodistrian University of Athens, Athens, Greece.
Barbara BurtnessDepartment of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA; Department of Internal Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA. Electronic address: david.rimm@yale.edu.
Yale University · USFox Chase Cancer Center · USNational and Kapodistrian University of Athens · GRUniversity of Wisconsin Carbone Cancer Center · USWayne State University · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Zachary Scott Morris · 2022 to 2026
$12.5M
Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck CancerP50DE030707 · NIDCR · YALE UNIVERSITY · PI BURTNESS, BARBARA · 2020 to 2024
$11.8M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA196530NCI NIH HHS P50 CA278595NIDCR NIH HHS P50 DE030707
6 · The paper itself

Abstract

purposeThe prognostic and predictive significance of pathologist-read tumor infiltrating lymphocytes (TILs) in head and neck cancers have been demonstrated through multiple studies over the years. TILs have not been broadly adopted clinically, perhaps due to substantial inter-observer variability. In this study, we developed a machine-based algorithm for TIL evaluation in head and neck cancers and validated its prognostic value in independent cohorts. EXPERIMENTAL

designA network classifier called NN3-17 was trained to identify and calculate tumor cells, lymphocytes, fibroblasts and "other" cells on hematoxylin-eosin stained sections using the QuPath software. These measurements were used to construct three predefined TIL variables. A retrospective collection of 154 head and neck squamous cell cancer cases was used as the discovery set to identify optimal association of TIL variables and survival. Two independent cohorts of 234 cases were used for validation.

resultsWe found that electronic TIL variables were associated with favorable prognosis in both the HPV-positive and -negative cases. After adjusting for clinicopathologic factors, Cox regression analysis demonstrated that electronic total TILs% (p = 0.025) in the HPV-positive and electronic stromal TILs% (p < 0.001) in the HPV-negative population were independent markers of disease specific outcomes (disease free survival).

conclusionsNeural network TIL variables demonstrated independent prognostic value in validation cohorts of HPV-positive and HPV-negative head and neck cancers. These objective variables can be calculated by an open-source software and could be considered for testing in a prospective setting to assess potential clinical implications.

Indexed as

AlgorithmsHead and Neck NeoplasmsLymphocytes, Tumor-InfiltratingAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkerHead and neck cancerHPVPrognosisQuPathTILs

Identifiers

PMID38547779
PMCPMC11060915
OpenAlexW4393224086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.